Fred Rohm, DO
Family Medicine · Fort Worth, TXNPI 1407894926
Payments from drug & device makers
Across 355 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$798
- AstraZeneca$463
- Amarin Pharma, Inc.$412
- Amgen$387
- AbbVie$387
- Lilly USA, LLC$343
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,42999%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $798 |
| AstraZeneca | 28 | $463 |
| Amarin Pharma, Inc. | 31 | $412 |
| Amgen | 17 | $387 |
| AbbVie(2 entities) | 23 | $387 |
| Lilly USA, LLC | 24 | $343 |
| GSK | 14 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $243 |
| Eisai Inc. | 14 | $229 |
| Pfizer | 12 | $181 |
| Lucid Diagnostics Inc. | 12 | $157 |
| Johnson & Johnson | 11 | $148 |
| Bayer | 8 | $112 |
| Boehringer Ingelheim | 7 | $97 |
| Astellas Pharma US Inc | 6 | $90 |
| Merck | 7 | $90 |
| Hikma Pharmaceuticals USA | 5 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Sumitomo Pharma America, Inc. | 4 | $84 |
| Biohaven Pharmaceuticals, Inc. | 4 | $81 |
| Nevro Corp. | 3 | $76 |
| Novartis | 5 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Bristol Myers Squibb | 4 | $59 |
| Seqirus USA Inc | 2 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Upsher-smith Laboratories LLC | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Genentech USA, Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Abbott | 1 | $20 |
| Dexcom, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$123
- Xultophy 100/3.6$116
How this compares
$5,475 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $59,513 |
| EliquisApixaban | 41 | $52,494 |
| MounjaroTirzepatide | 48 | $52,109 |
| OxycontinOxycodone Hcl | 11 | $47,990 |
| TrulicityDulaglutide | 28 | $43,709 |
| RexultiBrexpiprazole | 25 | $37,084 |
| MyrbetriqMirabegron | 44 | $36,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $35,276 |
| FarxigaDapagliflozin Propanediol | 19 | $17,701 |
| TrintellixVortioxetine Hydrobromide | 21 | $16,458 |
| XareltoRivaroxaban | 12 | $13,687 |
| JardianceEmpagliflozin | 13 | $11,570 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 193 | $9,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,147 |
| VascepaIcosapent Ethyl | 17 | $6,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $343 | $95,81876 claims |
| Novo NordiskOzempic | $798 | $59,51352 claims |
| PfizerEliquis, Premarin | $181 | $57,76157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $68 | $37,08425 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $36,71844 claims |
| GSKTrelegy Ellipta | $258 | $35,27644 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $463 | $25,84732 claims |
| Johnson & JohnsonXarelto, Invokana | $148 | $20,01423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $243 | $16,45821 claims |
| Boehringer IngelheimJardiance | $97 | $11,57013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.